SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 24, 2021
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
353 Hatch Drive
Foster City, California
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants Telephone Number, Including Area Code: (650) 837-0111
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock, $0.001 par value per share||PCVX||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
On March 24, 2021, Vaxcyte, Inc. (the Company) was made aware of allegations of sexual harassment and inappropriate conduct towards an employee of GlaxoSmithKline plc (GSK) by Moncef Slaoui, Ph.D., the Chairman of the Companys Board of Directors (the Board), which occurred when he was an employee of GSK.
Based on these allegations and in alignment with Vaxcytes corporate values and policies, the Board has requested Dr. Slaouis resignation. Dr. Slaoui has agreed and has resigned from the Board effective immediately.
Dr. Slaoui joined the Board in July 2017 and became Chairman of the Board in May 2018. Dr. Slaoui also served on the Compensation Committee. Dr. Slaouis resignation was not the result of any dispute or disagreement with the Company or the Companys Board on any matter relating to the operations, policies or practices of the Company.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|Date: March 24, 2021||VAXCYTE, INC.|
|President and Chief Financial Officer|